Two Sigma Advisers
TEVA icon

Two Sigma Advisers’s Teva Pharmaceuticals TEVA Stock Holding History

Two Sigma Advisers’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-7,000
Closed -$376K – 2763
2014
Q3 		$376K Buy
+7,000
New +$371K ﹤0.01% 1715

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Advisers's TEVA Position: Q1 2026 in Review

Two Sigma Advisers sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 150,000 shares — an estimated $4.68M sold.

Two Sigma Advisers first reported a position in TEVA in Q2 2013 and held it in 45 quarters. The position peaked at $148M in Q1 2017. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Two Sigma Advisers reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 150,000 Teva Pharmaceuticals shares in Q1 2026, an estimated $4.68M.
  • Two Sigma Advisers first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 45 quarters.
  • Two Sigma Advisers's Teva Pharmaceuticals position peaked at $148M in Q1 2017.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.